Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer

St. John Providence Health System

Status and phase: Unknown; Phase 2

Conditions: Non-Small Cell Lung Cancer

Treatments: Drug: bevacizumab; Drug: gemcitabine; Drug: carboplatin

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00150657

AVF3121s

Details and patient eligibility

About

• this study is being done to find out if the combination of carboplatin and gemcitabine will be more effective in the the treatment of advanced lung cancer if bevacizumab, an agent that blocks tumor blood vessel formation, is added
• the study will measure the time to progression of patients treated with the combination; we hope to show that the addition of bevacizumab improves the time to progression (increases the amount of time before the disease begins to worsen)
• all patients receive all three drugs; there is no placebo

Full description

• Patients with advanced (stage IV, and Stage IIIB with effusion) non-small cell lung cancer with non-squamous histology, good performance status, and adequate organ function are eligible.
• Patients with brain metastases, squamous histology, or hemoptysis are excluded.
• All patients must give informed consent.
• Schema gemcitabine 1250 mg/M2 IV day 1,8 carboplatin AUC 5 IV day 1 bevacizumab 15 mg/kg IV day 1 repeated every 21 days for 6 cycles

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically or cytologically proven non-small cell lung cancer, newly diagnosed or recurrent after previous surgery and/or radiation therapy
• Stage IV disease or stage IIIB with a malignant pleural effusion
• measurable or evaluable disease
• Performance status 0 or 1 (ECOG)
• adequate renal, hepatic, and bone marrow function
• adequate recovery from previous surgery or radiotherapy
• informed consent

Exclusion criteria

• brain metastases
• squamous (epidermoid) histology
• hemoptysis
• central airway disease
• Pancoast tumors
• previous chemotherapy or biologic therapy for lung cancer
• prior malignancy within the previous 5 years except non-melanoma skin cancer or cervical CIS
• pregnant or nursing women

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)